Novo Nordisk A/S NVO
Novo Nordisk A/S (NYSE: NVO) is a cardio-renal-metabolic drug developer. Its lead program, Semaglutide franchise (Ozempic, Wegovy, Rybelsus) and GLP-1/insulin portfolio, is in Phase 3 for Type 2 diabetes and obesity.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Ozempic / Rybelsus (semaglutide) | Type 2 diabetes | protein/peptide | Approved |
| Wegovy (injectable and oral Wegovy Pill) / Saxenda | Obesity | protein/peptide | Approved |
| Insulin portfolio (Tresiba, NovoLog/NovoRapid, Fiasp, Levemir, Xultophy) | Diabetes | protein/peptide | Approved |
| Rare disease (Norditropin growth hormone, NovoSeven haemophilia) | Growth disorders, haemophilia | protein/peptide | Approved |
| Efruxifermin (EFX), acquired with Akero Therapeutics December 2025 | MASH (metabolic dysfunction-associated steatohepatitis) | protein/peptide | Phase 3 |
Recent results and decisions
- Aug 4, 2026missed ZEUS phase 3 cardiovascular outcomes trial did not meet its primary endpoint (update provided in July).
The trial did not meet its primary endpoint.
Filing - Aug 4, 2026mixed REIMAGINE 4 vs tirzepatide 15 mg: non-inferior for weight (15.2% vs 15.8%) but not for HbA1c (-1.9 vs -2.2 points).
CagriSema 2.4 mg/2.4 mg demonstrated non-inferiority versus tirzepatide 15 mg for weight reduction, but not for HbA1c reduction.
Filing - Aug 4, 2026met REDEFINE 9: both lower CagriSema doses achieved superior weight loss vs placebo at 68 weeks.
CagriSema 1.0 mg/1.0 mg and 1.7 mg/1.7 mg achieved a superior weight loss compared to placebo.
Filing
37 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.